{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:31:19Z","timestamp":1771270279647,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.nmd.2019.11.007","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T20:15:17Z","timestamp":1574367317000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Discontinuation of enzyme replacement therapy in adults with Pompe disease: Evaluating the European POmpe Consortium stop criteria"],"prefix":"10.1016","volume":"30","author":[{"given":"H.A.","family":"van Kooten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Harlaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.A.M.E.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Brusse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.L.","family":"van der Pol (Chair)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Brusse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.A.M.","family":"Ditters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Harlaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Hoogendijk-Boon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.H.","family":"Huidekoper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.J.O.","family":"Kompanje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Oskam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.W.M.","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.J.","family":"Sibbles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.A.","family":"van den Dorpel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.A.M.E.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.P.","family":"van der Hout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"van der Kuy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.A.","family":"van Kooten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.G.","family":"Vulto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.E.M.","family":"Wagenmakers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9646","key":"10.1016\/j.nmd.2019.11.007_bib0001","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.nmd.2019.11.007_bib0002","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.nmd.2019.11.007_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","article-title":"Childhood Pompe disease: clinical spectrum and genotype in 31 patients","volume":"11","author":"van Capelle","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.nmd.2019.11.007_bib0004","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"issue":"9\u201310","key":"10.1016\/j.nmd.2019.11.007_bib0005","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"Muller-Felber","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.nmd.2019.11.007_bib0006","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.nmd.2010.07.277","article-title":"Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study","volume":"20","author":"van Capelle","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nmd.2019.11.007_bib0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J Neurol"},{"issue":"15","key":"10.1016\/j.nmd.2019.11.007_bib0008","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nmd.2019.11.007_bib0009","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","article-title":"Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up","volume":"39","author":"Gungor","year":"2016","journal-title":"J Inherit Metab Dis"},{"issue":"23","key":"10.1016\/j.nmd.2019.11.007_bib0010","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.11.007_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"Gungor","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.nmd.2019.11.007_bib0012","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2019.11.007_bib0013","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.nmd.2019.11.007_bib0014","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"van der Ploeg","year":"2017","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2019.11.007_bib0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.nmd.2014.09.016","article-title":"Muscle ultrasound in classic infantile and adult Pompe disease: a useful screening tool in adults but not in infants","volume":"25","author":"Vill","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2019.11.007_bib0016","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF00313939","article-title":"Measuring muscle strength","volume":"231","author":"van der Ploeg","year":"1984","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2019.11.007_bib0017","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jnnp.54.3.244","article-title":"Hand-held myometry: reference values","volume":"54","author":"van der Ploeg","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.nmd.2019.11.007_bib0018","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10545-011-9388-3","article-title":"The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients","volume":"35","author":"van Capelle","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2019.11.007_bib0019","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","article-title":"Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study","volume":"7","author":"de Vries","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.nmd.2019.11.007_bib0020","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.nmd.2019.11.007_bib0021","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2019.11.007_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.nmd.2019.11.007_bib0023","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ymgme.2011.04.009","article-title":"Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered","volume":"103","author":"El-Gharbawy","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"9","key":"10.1016\/j.nmd.2019.11.007_bib0024","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s00415-014-7402-z","article-title":"Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis","volume":"261","author":"Hundsberger","year":"2014","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.nmd.2019.11.007_bib0025","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s00415-018-9065-7","article-title":"36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry","volume":"265","author":"Scheidegger","year":"2018","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2019.11.007_bib0026","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","article-title":"Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years","volume":"117","author":"Stepien","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2019.11.007_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2017.06.007","article-title":"Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme(R)) in 12 patients with advanced late-onset Pompe disease","author":"Papadopoulos","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"7","key":"10.1016\/j.nmd.2019.11.007_bib0028","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.nmd.2011.04.001","article-title":"Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease","volume":"21","author":"Orlikowski","year":"2011","journal-title":"Neuromuscul Disord"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896619312052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896619312052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:08:39Z","timestamp":1760774919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896619312052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0960896619312052"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2019.11.007","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of enzyme replacement therapy in adults with Pompe disease: Evaluating the European POmpe Consortium stop criteria","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2019.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}